GE HealthCare Announces FDA Approval of Flyrcado Injection PET Radiotracer for Enhanced Diagnosis of Coronary Artery Disease
September 28, 2024
September 28, 2024
CHICAGO, Illinois, Sept. 28 (TNSres) -- G.E. HealthCare issued the following news release:
* * *
* GE HealthCare's FDA-approved flurpiridaz F 18 PET radiotracer, Flyrcado, delivers higher diagnostic efficacy in patients with known or suspected coronary artery disease (CAD), compared to SPECT MPI, the predominant procedure used in nuclear cardiology today
* With a half-life over ten times longer than currently approved cardiac PET radiotracers, Flyrcado . . .
* * *
* GE HealthCare's FDA-approved flurpiridaz F 18 PET radiotracer, Flyrcado, delivers higher diagnostic efficacy in patients with known or suspected coronary artery disease (CAD), compared to SPECT MPI, the predominant procedure used in nuclear cardiology today
* With a half-life over ten times longer than currently approved cardiac PET radiotracers, Flyrcado . . .